Abstract: A milk calcium composition which is highly dispersible and tasty can be obtained by adjusting the pH of a permeate containing lactic acid and lactic acid ion, which was obtained by treating whey with a UF membrane or NF membrane, to recover milk calcium as a slurry-like precipitate and then admixing this milk calcium with milk proteins.

Abstract: Addition of a specific sugar compound to an iron-containing protein composition solution can provide an excellent freezing and thawing stability and restrained precipitate productivity in a thawed solution of its frozen product and increase the efficiency in the use of the iron-containing protein useful for enrichment of iron in a food or drink, production of iron preparations.

Abstract: A milk basic protein fraction is heated if necessary, the resulting precipitate is removed to recover the resulting supernatant, alcohol is added to this supernatant, a fraction containing a high concentration of milk basic cystatin is recovered by removing the resulting precipitate and brought into contact with a carrier containing a sulfuric acid group, such as heparin, to recover a fraction which is not adsorbed onto the carrier, and this fraction is then treated with an ultrafiltration membrane having an cut-off molecular weight of 10-50 kDa to recover the permeate to produce a fraction containing a high concentration of milk basic cystatin.

Abstract: A highly safe bone resorption suppressing agents, which can be used as medicines or admixed to food products or feeds, is produced. Milk-derived basic cystatins and/or milk-derived basic cystatin decomposition products prepared from milk are made into bone resorption suppressing agents, or admixed to drinks, food products and feeds.

Abstract: The invention relates to a lyophilized HGF preparation prepared by lyophilizing an aqueous solution containing HGF, and a lyophilized HGF preparation containing a stabilizer, sodium chloride, a buffer, and/or a surface active agent. According to the invention, HGF can be stabilized, and it can be stored for a long period.

Abstract: A periodontal disease preventive and ameliorative agent with milk-derived basic protein as its effective ingredient, which protein is obtained by contacting a milk or milk-derived ingredient with cation-exchange resin, and then eluting a fraction adsorbed by the resin using an elution solution and which protein has an isoelectric point within a range of 7.5˜11, and food/drink and a medicament such as toothpaste and gargling agents, which contain this periodontal disease preventive and ameliorative agent.

Abstract: Urea is readily isolated and recovered from natural products. Urea can be brought into the permeate side by treating a urea-containing fraction extracted from natural products or sewage containing urea, with a nanofiltration (NF) membrane or reverse osmotic (RO) membrane. A milk-derived composition containing urea at a level of more than 0.2% of the total solids can be obtained by treating natural products such as milk or milk materials with an NF membrane or RO membrane to bring a fraction containing urea into the permeate side.

Abstract: Folic acid and/or vitamin B12 and lactoferrin are mixed to produce a folic acid and/or vitamin B12-lactoferrin complex. The complex can be used for enriching foods or drink.

Abstract: A processed whey protein with an improved shelf life comprising partially heat-denatured whey protein and casein protein is provided. The partially heat-denatured whey protein can be prepared by heating a solution with a protein concentration of 0.5 to 15% by weight and pH 6-8 at 55 to 120° C. for 1 to 120 minutes. A process for the preparation of processed whey protein is also provided and comprises adding casein protein to partially heat-denatured whey protein, or adding casein protein to non-denatured whey protein and heating the mixture to partially denature the non-denatured whey protein. The processed whey protein has an improved shelf life. The gel obtained from the processed whey protein exhibits high water retention capacity and superior elasticity. The product is useful as a raw material of foods.

Abstract: An L-carnitine agent has an indispensable function in the body and utility as a material for pharmaceutical agents or food and drink. By subjecting milk or modified milk products of mammals from which casein is removed, to the treatment of desalting and partial removal of lactose followed by drying, L-carnitine content, lactose content, and ash content are adjusted to 0.1˜100 mmol/100 g, 20˜95 g/100 g, and 5 g/100 g or less, respectively.

Abstract: Milk is concentrated by filtering with an ultrafiltration (UF) membrane, after which casein is removed by acidification and the resulting liquid is concentrated and/or dried to produce a milk calcium composition having the following components' ratios (1) and (2): (1) −1.3≦log{(% by weight calcium in composition)/(% by weight protein in composition)}≦0.26; (2) 0.9≦log{(% by weight calcium in composition)/(% by weight sodium in composition)}.

Abstract: The present invention is to provide a novel medicine, drink, food or feed having an action of strengthening bone. More specifically, the present invention is to provide a medicine, drink, food or feed combined with collagen, fraction containing collagen or degradation product thereof. Fraction containing collagen was prepared by mincing skin corium layer into pieces, defatting it and lyophylization or by pulverizing bone, decalcifying it and lyophylization. Oral administration of these can stimulate proliferation of osteoblast, inhibit bone resorption and strengthen bone. They can be useful for improvement of osteoporosis, bone fracture, bone pain, etc.

Abstract: The new glycoprotein, which possesses an anti-tumor activity, a leukemia cell differentiation inducing activity, a cellular immunology enhancing activity, a vascular endothelial cell growth stimulating activity and a hepatocyte growth stimulating activity, can be obtained.

Abstract: A preventative and/or therapeutic agent to treat and/or prevent organ failure due to mercury exposure, contains as the active ingredient a mutant tumor cytotoxic factor protein (TCF-II). The therapeutic agent comprises a mutant TCF-II protein according to SEQ ID NO. 2 in which amino acid residues Arg-Lys-Arg-Arg have been replaced by Ala-Ala-Ala-Ala, or in which amino acids Lys-Ile-Lys-Thr-Lys-Lys have been replaced by Ala-Ile-Ala-Thr-Ala-Ala (SEQ ID NO. 3).

Abstract: A novel primer is provided which is useful in the reverse transcription polymerase chain reaction to amplify &agr;S1-casein gene and keratin gene contained in milk. A method is also provided for using the expression ratio of their genes to examine the pathological conditions of mammalian mastitis or determine the milk protein synthesis level in mammary gland cells. The method is quick and accurate and avoids the need for excising mammary gland tissue.

Abstract: A composition with a high ganglioside content is manufactured by a method characterized in that milk or milk-derived material containing ganglioside is dispersed in an ethanol solution so that the concentration of ethanol becomes 60˜95%; after removing the precipitate which is generated by heating the solution to a temperature higher than 50° C., the obtained supernatant is cooled to a temperature lower than 0° C; and the obtained precipitate is recovered. The obtained composition with a high ganglioside content is used advantageously as a material for foods and drinks, medicines, chemical products, etc.

Abstract: The invention provides a spread which contains phospholipids, has a 60% or less than 60% by weight oil phase, and exhibits an increase in conductivity at 36° C. to 0.2 mS/cm or more than 0.2 mS/cm in 300 seconds, and as such, forms a stable emulsion to produce a highly stable product, and when ingested, melts well and rapidly demulsifies to yield a sufficiently satisfying flavor.

Abstract: This invention provides carbonic acid- and/or hydrogencarbonic acid-iron-hydrolyzates of casein complexes containing a large amount of iron, without causing precipitation after heating their aqueous solution or astringent taste and the processes for production thereof. The complexes of the present invention are prepared by (1) partial hydrolysis of carbonic acid- and/or hydrogencarbonic acid-iron-casein complexes with a protease or (2) mixing carbonic acid and/or hydrogencarbonic acid, iron and partial hydrolyzates of casein with a protease. These complexes are used favorably as food additives, raw materials of medicines or feed components due to their lack of precipitation by heating their aqueous solution, or astringent taste.

Abstract: The present invention relates to a method of synchronizing epithelial cells into G.sub.0 phase, more specifically, a method of synchronizing epithelial cells into G.sub.0 phase characterized by culturing the cells in a synthetic medium for 5 days or more, wherein said synthetic medium is a medium with the lowered concentration of bovine fetal serum 5% or less and said epithelial cells is bovine mammary gland cells. Further, the present invention relates to a method of culturing cells characterized by using G.sub.0 phase synchronized cells obtained by the present invention, and a method of screening a related to differentiation and/or maturation of said cells by using G.sub.0 phase synchronized cells. The present invention is useful for easily synchronizing epithelial cells into G.sub.0 phase and for screening a factor related to differentiation and/or maturation of epithelial cells.

Abstract: The present invention provides new benzofuranone derivatives and a method for producing the derivatives useful for a therapeutic agent for preventing and/or treating hormone dependent diseases.The present invention is a new benzofuranone derivative represented by a particular general formula (I). ##STR1## In the production, a particular benzofuranone compound and a particular benzaldehyde are reacted.